Paolo Paoletti, GammaDelta Therapeutics CEO
October 27, 2021 09:51 AM EDTUpdated 04:18 PM
Deals
R&D

Take­da swoops in and scoops up a cell ther­a­py start­up in buy­out deal, ex­pand­ing on­col­o­gy pipeline

John Carroll

Editor & Founder

A lit­tle more than 4 years af­ter Take­da stepped in to help bankroll the T cell start­up Gam­maDelta Ther­a­peu­tics with a cool $100 mil­lion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Take­da to pay $200M for rights to ane­mia drug from Keros

Janux soars on ear­ly prostate can­cer da­ta that could chal­lenge No­var­tis' Plu­vic­to

Rev­o­lu­tion sells $600M in shares on back of RAS in­hibitor port­fo­lio up­dates

Roche teams up with Chica­go au­toim­mune biotech COUR Phar­ma­ceu­ti­cals

Ipsen se­cures rights to pre­clin­i­cal T cell en­gager in $610M pact with French biotech

Gilead makes an­oth­er ADC move, ink­ing up to $415M pact with Tubu­lis

A service from the Financial Times